Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine (RP101)

This study has been terminated.
Information provided by:
SciClone Pharmaceuticals Identifier:
First received: October 25, 2007
Last updated: June 6, 2011
Last verified: October 2009
This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic pancreatic cancer. The study will be conducted at approximately 55 sites in the North American, Europe, and South America. Approximately 153 subjects will be enrolled in a randomization (ratio 2:1).

Condition Intervention Phase
Pancreatic Cancer
Drug: RP101
Drug: Gemcitabine (1000 mg/m2)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Health Services Research
Official Title: Randomized, Double Blind, Placebo Controlled, Phase 2 Study Evaluating the Efficacy & Safety of RP101 or Placebo in Combination With Gemcitabine Administered as First-Line Treatment to Subjects With Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma

Resource links provided by NLM:

Further study details as provided by SciClone Pharmaceuticals:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression Free Survival [ Time Frame: 14 months ] [ Designated as safety issue: No ]
  • Evaluate the CA 19-9 levels [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Compare changes in ECOG [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Evaluate Safety of RP101 [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 153
Study Start Date: September 2007
Study Completion Date: October 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1
RP101 and Gemcitabine
Drug: RP101
190 mg oral tablet
Drug: Gemcitabine (1000 mg/m2)
30 minute intravenous infusion
Other Name: Gemzar
Placebo Comparator: Arm 2
Placebo and Gemcitabine
Drug: Gemcitabine (1000 mg/m2)
30 minute intravenous infusion
Other Name: Gemzar


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be 18 years of age or older
  • Not previously treated with chemotherapy for Pancreatic Cancer
  • ECOG performance status of 0 or 1
  • Life expectancy > 3 months
  • Documentation of all sites of pancreatic disease within 28 days prior to randomization
  • Adequate hematological, renal, and hepatic function
  • Not pregnant or nursing
  • Fertile subjects must practice a medically approved method of contraception

Exclusion Criteria:

  • Prior history of other malignant tumors
  • Participation in another investigational study within 4 weeks prior to treatment start
  • Major surgery within 14 days prior to treatment start
  • Radiation treatment within 28 days prior to treatment start
  • Uncontrolled cardiac atrial or ventricular arrhythmias
  • Gastrointestinal tract disease such resulting in an inability to take oral medication
  • Known to be seropositive for HIV, HBV, or HCV
  • Uncontrolled cancer pain
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00550004

  Show 55 Study Locations
Sponsors and Collaborators
SciClone Pharmaceuticals
Study Chair: Manuel Hidalgo, MD, PhD Centro Integral de Oncologia
  More Information

Additional Information:
Responsible Party: Israel Rios, M.D, Sciclone Pharmaceuticals, Inc. Identifier: NCT00550004     History of Changes
Other Study ID Numbers: SCI-RP-Pan-P2-001 
Study First Received: October 25, 2007
Last Updated: June 6, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by SciClone Pharmaceuticals:
locally advanced
metastatic pancreatic adenocarcinoma
Stage III
Stage IV

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on May 03, 2016